3 December 2015 - NICE has today published draft guidance as part of its highly specialised technologies programme that does not recommend asfotase alfa (Strensiq, Alexion Pharmaceuticals) for treating paediatric-onset hypophosphatasia.

For more details, go to: http://www.nice.org.uk/news/press-and-media/benefits-of-new-drug-to-treat-rare-inherited-bone-disorder-too-uncertain-to-justify-its-high-cost-says-nice-in-draft-guidance